



UNIVERSITY OF LEEDS

This is a repository copy of *A Large Increase In Anti-Melanoma-Differentiation-Associated-Gene-5 (Mda5) Antibody Positivity And Associated Disease In Yorkshire Since 2020*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/212581/>

Version: Accepted Version

Proceedings Paper:

Iqbal, K., De Marco, G. orcid.org/0000-0003-2406-161X, Maisuria, S. et al. (16 more authors) (2023) *A Large Increase In Anti-Melanoma-Differentiation-Associated-Gene-5 (Mda5) Antibody Positivity And Associated Disease In Yorkshire Since 2020*. In: *Annals of the Rheumatic Diseases*. EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , p. 944.

<https://doi.org/10.1136/annrheumdis-2023-eular.6416>

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. This is an author produced version of a conference abstract published in *Annals of the Rheumatic Diseases*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Abstract N°: 6416

Myositis

A Large increase in Anti-Melanoma-Differentiation-Associated-Gene-5 (MDA5) Antibody Positivity and Associated Disease in Yorkshire since 2020

Khizer Iqbal¹, Gabriele De Marco^{*2, 3}, Sheetal Maisuria⁴, Gururaj Arumugakani^{4, 5}, Zoe Ash⁶, Catrin Buckley¹, Lauren Coles¹, Chamila Hettiarachchi⁷, Mansoor Keen⁶, Catherine Lawson⁸, Joanna Mclorinan¹, Sharmin Nizam⁷, Hanu Reddy⁹, Omer Sharif¹⁰, Shabina Sultan⁹, Gui Tran⁸, Mark Wood¹, Samuel Wood¹, Dennis Mcgonagle²

¹Leeds Teaching Hospitals NHS Trust, Rheumatology, Leeds, United Kingdom, ²University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Pathology, Leeds, United Kingdom, ⁵University of Leeds, Immunology, Leeds, United Kingdom, ⁶Bradford Teaching Hospitals NHS Foundation Trust, Rheumatology, Bradford, United Kingdom, ⁷Mid Yorkshire Hospitals NHS Trust, Rheumatology, Wakefield, United Kingdom, ⁸Harrogate and District NHS Foundation Trust, Rheumatology, Harrogate, United Kingdom, ⁹Airedale NHS Foundation Trust, Rheumatology, Steeton with Eastburn, United Kingdom, ¹⁰Calderdale and Huddersfield NHS Foundation Trust, Rheumatology, Huddersfield and Halifax, United Kingdom

Background:

Melanoma differentiation-associated protein 5 (MDA5) is an intracellular detector of viral RNA. It is considered that viral infections are involved in the aetiology of autoimmune diseases, including autoimmune myositis. Previously we reported on a post-COVID-19 pandemic cluster of myositis occurring in the Yorkshire region (De Marco, 2022), despite the usually low frequency observed in the UK. More recently, we noticed increased anti-MDA5 positivity rate in myoblot tests.

Objectives:

Our aim is to appraise the significance of the observed increased anti-MDA5 positivity recognized at our tertiary centre.


Methods:

The Leeds Teaching Hospitals NHS Trust serves as an immunology laboratory reference for the wider Yorkshire region (3.6 million residents). We audited the increased anti-MDA5 positivity in relationship to other muscle-specific autoantibodies (Euroimmun immunoblot©) analysing retrospectively all tests performed between January 2018 and December 2022. Clinical notes review focused on: MDA5+ without disease; patterns of symptomatic MDA5 disease (including degree of ILD); muscle or other organs involvement; response to therapy. We also appraised the temporal associations between recent COVID-19 infection and SARS-CoV-2 vaccination.

Results:

Requests for anti-MDA5 were stable between 2018 and 2020, but doubled thereafter. Anti-MDA5 positivity went from 0.6% to 4.9% in that period, dropping to 2.2% at the end of 2022 (Figure 1). Out

of 66 individuals testing positive for anti-MDA5, clinical notes were available in 50 cases. Eleven had myositis without ILD (7 had dermatomyositis/"mechanic" hands rash). 18/50 cases developed ILD (12 had also myositis associated pathology, including 5 dermatomyositis rash and 5 "mechanic" hands). No cases of carditis were recorded. After treatment, outcome was stable/improved in 17 cases (6 ILD cases). Yet, 3 cases worsened and 6 died despite therapy (ILD cases). Twenty cases had signs described as within the connective tissues diseases spectrum (without any lung involvement), though no formal diagnosis. A minority of cases were associated with evidence of SARS-CoV-2 infection or vaccination, with 15 cases vaccinated before disease onset and 4 with preceding COVID-19 infection.



Summary per year	2018	2019	2020	2021	2022
Number of requests	364	535	459	812	1011
Number of patients	339	505	425	726	947
Total MDA5 Ab positive	4	3	10	40	22
New MDA5 Ab positive	4	2	9	35	17
Percentage positive (of total requests)	1.1	0.6	2.2	4.9	2.2

Conclusion:

Our data show an increased rate of anti-MDA5 positivity in the latter stages of the COVID-19 pandemic, as previously noted in the UK (Hannah J, ACR 2022). Most cases had MDA5 positivity without confirmed autoimmune disease and despite the MDA5 positivity occurrence in the face of the COVID-19 pandemic further longitudinal observation is needed to ascertain any potential links with either infection, vaccination or both.

References:

- 1) DeMarco G, et al Vaccines (Basel) 2022; 10: 1184.
- 2) Hannah J, et al. ACR Convergence Meeting 2022; Abstract Number: 1857

Acknowledgements:

Disclosure of interest: None declared